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Autoinflammatory diseases (AIDs) are a genetically heterogeneous group of diseases 
caused by mutations of genes encoding proteins, which play a pivotal role in the 
regulation of the inflammatory response. In the pathogenesis of AIDs, the role of the 
genetic background is triggered by environmental factors through the modulation of the 
innate immune system. Monogenic AIDs are characterized by Mendelian inheritance and 
are caused by highly penetrant genetic variants in single genes. During the last years, 
remarkable progress has been made in the identification of disease-associated genes 
by using new technologies, such as next-generation sequencing, which has allowed 
the genetic characterization in undiagnosed patients and in sporadic cases by means 
of targeted resequencing of a gene panel and whole exome sequencing. In this review, 
we delineate the genetics of the monogenic AIDs, report the role of the most common 
gene mutations, and describe the evidences of the most sound genotype/phenotype 
correlations in AID.
Keywords: autoinflammatory diseases, hereditary periodic fevers, familial Mediterranean fever, mevalonate-kinase 
deficiency, tumor necrosis factor receptor-associated periodic syndrome, cryopyrinopathies, inflammasome, 
whole exome sequencing
iNTRODUCTiON
The term autoinflammatory disease (AID) was proposed in 1999 to describe a group of disorders of 
the innate immune system characterized by recurrent episodes of inflammation without a known 
origin (1). AIDs are frequently caused by genetic mutations in genes encoding proteins involved 
in the pathways of the inflammasome, with a crucial role of proinflammatory interleukin-1 (IL-1), 
which is an important cytokine of the systemic inflammatory response.
Autoinflammatory diseases have in the most of cases a genetic background, with highly penetrant 
mutations of single genes, but in some cases are polygenic, with a strong environmental influence 
that can modulate the phenotype (2).
The first AID described was the familial Mediterranean fever (FMF), which is also the most 
prevalent AID in the world. After FMF, other two AIDs were described: TNF-receptor associated 
periodic syndrome (TRAPS) (1) and hyperimmunoglobulinemia D with periodic fever syndrome 
[hyper-IgD syndrome (HIDS)/mevalonate kinase (MVK)] (3–5). These three forms of AID were 
grouped in the hereditary periodic fever syndromes, because they share fever episodes. After these, 
TABLe 1 | Classification of monogenic autoinflammatory diseases (AiDs).
Disorder (abbreviation) #OMiM Gene (Locus) Protein involved inheritance
Familial Mediterranean fever 249100 MEFV (16p13.3) Pyrin (marenostrin) Autosomal recessive
Hyper-IgD syndrome 260920 MVK (12q24.11) Mevalonate kinase Autosomal recessive
Mevalonate kinase deficiency 260920 MVK (12q24) Mevalonate kinase Autosomal recessive
Tumor necrosis factor receptor-associated periodic syndrome 142680 TNFRSF1A (12p13) Tumor necrosis factor receptor type-1 Autosomal dominant
Familial cold autoinflammatory syndrome (FCAS) 120100 NLRP3 (1q44) Cryopyrin Autosomal dominant
Muckle–Wells syndrome 191900 NLRP3 (1q44) Cryopyrin Autosomal dominant
Neonatal onset multisystem inflammatory disease 607115 NLRP3 (1q44) Cryopyrin Autosomal dominant
Deficiency of interleukin (IL)-1 receptor antagonist 612852 IL1RN (2q) IL-1 receptor antagonist Autosomal recessive
Blau syndrome 186580 NOD2/CARD15 
(16q12.1-13)
Nucleotide-binding oligomerization 
domain-containing protein 2
Autosomal dominant
Deficiency of the IL-36 receptor antagonist 614204 IL36RN (2q14) IL-36 receptor antagonist Autosomal recessive
Chronic atypical neutrophilic dermatosis with lipodystrophy and 
elevated temperature syndrome
256040 PSMB8 (6p21) Inducible subunit β of the proteasome Autosomal recessive
Majeed syndrome 609628 LPIN2 (18p11.31) Lipin 2 Autosomal recessive
CARD14-mediated pustular psoriasis 177900 CARD14 (17q25.3) Caspase recruitment domain family 
member 14
Autosomal dominant
NLRP12-autoinflammatory disease 609648 NLRP12 (19q13.42) Monarch 1 Autosomal dominant
Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome 604416 PSTPIP1 (15q24-25) CD2 antigen-binding protein 1 Autosomal dominant
Deficiency of adenosine deaminase 2 615688 CECR1 (22q11.1) Adenosine deaminase 2 Autosomal recessive
STING-associated vasculopathy 615934 TMEM173 (5q31.2) Transmembrane protein 173 Autosomal dominant
TNFRSF11A-associated disease 603499 TNFRSF11A (18q21.33) Tumor necrosis factor receptor 11A Autosomal dominant
NLRC4-associated diseases (NLRC4-MAS, SCAN4, NLRC4-FCAS) 606831 NLRC4 (2p22.3) NLR family CARD domain-containing 
Protein 4
Autosomal dominant
Sideroblastic anemia, B-cell immunodeficiency, periodic fevers, 
developmental delay
616084 TRNT1 (3p26.2) CCA-adding enzyme Autosomal recessive
Monogenic form of systemic juvenile idiopathic arthritis 613409 LACC1 (13q14.11) Laccase (multicopper oxidoreductase) 
domain containing 1
Autosomal recessive
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other AIDs were identified, such as familial cold autoinflamma-
tory syndrome (FCAS), Muckle–Wells syndrome (MWS), and 
neonatal onset multisystem inflammatory disease (NOMID), 
also known as chronic infantile neurologic cutaneous and articu-
lar (CINCA) syndrome, then grouped in the cryopyrinopathies. 
These disorders are also known as cryopyrin-associated periodic 
syndromes (CAPS).
Recently, mutations in single genes involved in IL-1 processing 
have been demonstrated in the deficiency of IL-1 receptor antago-
nist (DIRA) (6). After this, evidences of drugs able to block IL-1 
in the Majeed syndrome (MS), an AID bone disease with clinical 
similarities to DIRA, demonstrated the pivotal role of IL-1 in 
this disorder (7). The same drug was used for cryopyrinopathies 
and DIRA, further expanding its use to other monogenic AID 
disorders. Other granulomatous disorders are characterized by 
typical granulomatous formations: Blau syndrome (familial juve-
nile systemic granulomatosis) is characterized by granulomatous 
inflammation of joint, skin, and uvea.
In this review, we will focus only on monogenic AIDs, which 
are mostly represented by early-onset conditions and a clear 
pattern of autosomal dominant or recessive transmission, at least 
in some of the families (Table 1) and the clinical significance of 
exonic variants according with pathogenic criteria (Table 2). The 
review will analyze the evidences about the mutations in the genes 
involved in the pathogenesis of the disease and the genotype/
phenotype correlations (8).
Familial Mediterranean Fever
Familial Mediterranean fever is the most common AID, which is 
inherited as autosomal recessive disease, although features of auto-
somal dominant pattern of transmission have been demonstrated 
in several families (9). This different pattern might have conferred 
an evolutionary advantage in the resistance to an endemic patho-
gen; in fact, Clostridium, Yersinia, Vibrio parahaemolyticus VopS, 
Histophilus somni IbpA, Burkholderia, and other microbes that 
modify RhoGTPases are able to stimulate pyrin inflammasome. 
Pyrin play a role in sensing pathogen modification and inactiva-
tion of Rho GTPases (10,11). Furthermore, in some populations, 
as Sephardic Jews, Turks, Arabs, and Armenians, the carrier rate 
for a mutant MEFV allele is high, ranging from 1/3 to 1/6; this 
represents the highest carrier rates reported for an autosomal 
recessive disorder.
To estimate prevalence in FMF is difficult, because of the 
wide range of differences in areas of diffusion of the disease. In 
particular, the most affected patients belong to Middle Eastern 
living around the Mediterranean Sea areas.
The causing gene, MEFV, was identified in 1997 by two 
International Consortia, who named the encoded protein pyrin/
marenostrin (11, 12), an intracellular regulator of IL-1 produc-
tion (13, 14). The disease-causing mutations spread all over the 
gene, even if the exon 10 carries the most typical and severe 
mutation; in fact, this exon encodes for the B30.2/SPRY domain 
at the C-terminal end of pyrin, which is demonstrated to interact 
TABLe 2 | Clinical significance of exonic variants according with the pathogenic criteria of Clinvar database (https://www.ncbi.nlm.nih.gov/clinvar/) for 
genes MEFV, MVK, TNFRSF1A, and NLRP3.
Gene Clinical significance
Conflicting interpretation Benign Likely benign Uncertain significance Likely pathogenic Pathogenic
MEFV Leu110Pro Leu110Pro Glu148Gln Ser6Arg Gly304Arg Glu148Gln
Glu148Gln Glu148Gln Arg202Gln Val33Leu Pro369Ser Glu148Val
Glu148Val Gly196Trp Gly304Arg Arg42Trp Arg408Gln Glu167Asp
Gly196Trp Arg202Gln Arg408Gln Asn78Ile Met680Ile Pro180Gln
Gly304Arg Pro369Ser Ile591Thr Asn78Ser Lys695Arg Thr267Ile
Pro369Ser Arg408Gln Glu84Gln Ala744Ser Glu276Ter
Arg408Gln Glu93Gln Leu367Val
Ile591Thr Gln97Ter Pro369Ser
Lys695Arg Asp103His His404Arg
Ser108Arg Thr577Asn
Leu110Pro Arg478Gln
Pro115Thr His478Tyr
Asp122Gly Phe479Leu
Gly136Glu Ile591Thr
Gln146Ter Arg653His
Pro147Ala Met680Ile
Glu148Gln Gly687Asp
Glu148Alafs Tyr688Ter
Glu148Val Ile692del
Arg151Thr Met694Val
Glu163Gln Met694del
Ala171Thr Lys695Arg
Gln172Pro Val726Ala
Pro183Thr Ala744Ser
Ala193Thr Arg761His
Gly196Trp
Glu230Lys
Lys266Glu
Gly304Arg
Thr309Met
Ala311Val
Arg314His
Gly320Ala
Arg329His
Ser339Phe
Arg348His
Gln356Glu
Pro369Ser
Pro383Arg
Arg480Gln
Gln440Glu
Glu446Ala
Lys447Asn
Ala457Val
Arg461Gln
Val469Ala
Asp505Tyr
Arg579His
Ile591Thr
Asn599Asp
Lys625Gln
Pro630Alafs
Arg653Cys
Gly678Glu
Lys695Arg
Pro714Leu
Lys716Glu
Phe743Leu
Ile772Val
Pro780Thr
MVK Val80Ile Arg19His Arg19Gln Pro11Leu Ile268Val Met1Thr
(Continued )
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Gene Clinical significance
Conflicting interpretation Benign Likely benign Uncertain significance Likely pathogenic Pathogenic
Ser52Asn Ser52Asn Val15Ala Leu6Glyfs
Val180Ile Cys21Ser His20Pro
Leu27Phe Gly25Trpfs
Val80Ile Leu41Pro
Cys101Tyr Tyr116His
Arg106His Gly140Argfs
Ala111Thr Ala141Glyfs
Pro200Ser Ala148Thr
Pro286Leu Pro165Leu
Gln302Ter Pro167Leu
Arg388Gln Trp188Ter
Gly202Arg
Val203Ala
Arg215Ter
Leu255Pro
Ile268Thr
Asn301Thr
Val310Met
Ala334Thr
Phe365Ser
Val377Ile
Arg388Ter
TNFRSF1A Arg121Gln None Pro75Leu Leu96Pro Asp41Glu Cys59Arg
Val112Met Phe89Leu Cys59Ser
Arg121Gln Asn94Lys Cys62Gly
Val124Met Arg106Gln Cys62Tyr
Asn145Ser Thr79Met
Glu178Lys Cys81Phe
Ile199Thr Cys99Ser
Pro269Arg Cys99Arg
Pro275Ser Cys117Arg
Pro412Ala Cys117Tyr
Ser452Arg Arg121Pro
Arg121Gln
NLRP3 Val198Met Gln705Lys Met70Thr Ala67Glu Leu305Pro Val198Met
Pro315Leu Val72Met Ala77Glu Arg488Lys Arg206Trp
Arg488Lys Ser196Asn Ala77Val Gln602Arg Asp303Asn
Gln705Lys Val198Met Arg100Cys Glu304Lys
Ser728Gly Pro315Leu Lys131Arg Phe309Ser
Thr954Met Arg488Lys Arg137His Thr348Met
His713Leu Asn165Ser Ala352Val
Ser728Gly Thr195Met Leu353Pro
Thr954Met Val198Met Thr405Pro
Asp212Asn Ala439Val
Ala225Val Gly569Arg
Gln250Arg Gly571Arg
Pro315Leu Phe573Ser
Lys357Arg Glu627Gly
Thr435Ala Tyr859Cys
Leu447Phe
Gly456Glu
Lys615Asn
Gln705Lys
Ser728Gly
Gly769Ser
Leu800Met
Gly811Ser
Leu832Ile
Ala848Pro
Ala873Thr
Lys880Glu
Thr915Met
TABLe 2 | Continued
(Continued )
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Gene Clinical significance
Conflicting interpretation Benign Likely benign Uncertain significance Likely pathogenic Pathogenic
Thr923Ala
Lys930Asn
Thr954Met
Cys990Ser
Cys998Ser
Lys1015Glu
TABLe 2 | Continued
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with the protein caspase 1 (15). Although five mutations repre-
sent more than 85% of all disease-associated mutations, many 
other mutations with different clinical penetrances have been 
reported so far (in the Infevers website more than 300 mutations 
are described) (16). Genetic test can support clinical diagnosis, 
confirming the presence of two mutations in the MEFV gene, 
although patients with a heterozygous mutation can show clinical 
pictures of FMF, even if with an incomplete phenotype (17).
In fact, there are evidences that the mutation in the second 
allele is not demonstrated in 20–25% of the patients with the 
clinical picture of FMF and a positive response to colchicine 
therapy (18). The reduced diagnostic accuracy of the genetic tests 
in terms of mutation finding is common to most of the genes 
studied for diagnostic purposes, since the diagnostic yield of the 
tests is never complete, due to factors like genetic heterogeneity, 
incorrect diagnosis, or phenocopies. When a heterozygous is 
found, the most obvious hypothesis is that the second disease 
allele lies in other genic regions not explored by the test (i.e., deep 
intronic regions); however, the second mutation has not been 
found also in studies analyzing the promoter and intron regions 
of the MEFV gene. In FMF, however, the evidence of autosomal 
dominant transmission, segregating a heterozygous mutation 
(17), or a complex allele (personal data) is consistent with a 
dosage effect, which is dependent on the type of the mutation, 
in analogy to models already described in other disease genes 
(i.e., GJB2, in which biallelic mutations cause autosomic reces-
sive nonsyndromic deafness and dominant mutations in specific 
domains of the gene cause syndromic forms of deafness with pal-
moplantar keratoderma). Another possible pathogenetic model 
for the dominant forms could involve the interaction of genetic 
and environmental factors in the pathogenesis of the disease, in 
analogy with hemochromatosis, in which heterozygotes for the 
C282Y in the HFE gene are bona fide healthy carriers unless 
other factors like alcohol or viral infections induce the onset of 
the clinical phenotype by contributing to the accumulation of 
iron in the liver. In a genomic study of 22 Belgian individuals, 12 
of whom had clinical pictures of AID, the pattern of Mendelian 
inheritance was autosomal dominant. The phenotype, different 
from FMF, was characterized by childhood-onset recurrent 
episodes of neutrophilic dermatosis, fever, elevated acute-phase 
reactants, arthralgia, and myalgia/myositis. The disease was 
named pyrin-associated autoinflammation with neutrophilic 
dermatosis (PAAND). Genomic analysis revealed a mutation in 
the MEFV gene, S242R. This mutation causes a loss of a binding 
motif in the pyrin protein different from the B30.2/SPRY domain. 
Interestingly, the loss of the S242 domain was observed in bac-
terial effectors able to activate the pyrin inflammasome, such 
as Clostridium difficile toxin B (TcdB). As a result, the S242R 
mutation has the same effect of pathogen sensing, acting as a 
trigger of the inflammasome activation and IL-1b production. 
Based on this fact, the affected patients were successfully treated 
with therapy targeted on IL-1b, resolving autoinflammation and 
neutrophilic dermatosis (19).
Another intriguing aspect in FMF and, more in general AID, 
is the different influences of certain mutations or polymorphisms 
on the phenotype. For example, an E148Q mutation is sometimes 
referred to as a functional polymorphism because of the high 
carrier rate (more than 10%) and the lack of phenotype in some 
homozygous patients. However, some patients may have severe 
disease expression as well. Thus, the suggestions put forward for 
the carrier state may apply to these states as well.
Environmental factors have been investigated in relation with 
disease severity in FMF (19). The strongest association correlated 
with amyloidosis was with the country of origin, not with the 
genotype. Another interesting study showed that Turkish children 
who are born and live in Turkey have a higher disease severity 
score compared with Turkish children living in Germany (20); 
this study demonstrated that the different patterns of infections 
influence the expression of the phenotype acting as a trigger of the 
weak innate immune pathway via pathogen-recognition factors.
In order to search for possible mutation in the MEFV gene, 
a multiplex ligation-dependent probe amplification was setup in 
216 FMF patients (21). No copy number variants were identified, 
suggesting that deletion/duplication is not a mutational mecha-
nism in MEFV. The possible functional explanation relies on the 
pyrin function, which is crucial in the immune surveillance, even 
if with genetic variants such as point mutations and functional 
polymorphisms able to modulate its function.
An interesting study aimed at investigating pyrin function 
during primate evolution analyzed the domain which contains 
the most MEFV mutations, named ret finger protein domain. 
Amino acids involved in MEFV mutations (653, 680, 681, 726, 
744, and 761 residues) in human are frequently present as wild 
type in other primates. In some cases, the mutant may be consid-
ered the reappearance of an ancestral amino acid state. As a result, 
an episodic positive selection was postulated. These changes in 
pyrin sequence could be caused by selective pressures driven 
from environmental agents (22).
Regarding the therapy, both a single mutation and two muta-
tions, supported by clinical pictures of FMF, support the use of 
6Martorana et al. Genetics of Monogenic AIDs
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colchicine (23). Amyloidosis type AA is frequently correlated 
with the MEFV mutation M694V and the SAA1.1/SAA1.1 
genotype (24).
In analogy with most of the disorders with pleiotropic expres-
sion, also for FMF, strict clinical criteria have been proposed for 
the diagnosis (25), taking into account the phenotypic manifes-
tations (the recurrence of fever with serositis), the histological 
picture (idiopathic AA amyloidosis), and the response to therapy 
(in typical FMF, the colchicine test results in a favorable 
response). Two major criteria are necessary for a definite 
diagnosis of FMF. Recurrent fever without serosal involvement, 
cutaneous, erysipelas-like manifestations, and a positive family 
history for the disease in a first-degree relative are considered 
minor criteria for the lower specificity of the features and take 
part in the algorithm for diagnosis only if a major criterion is 
present. The presence of two mutations in MEFV gene is gener-
ally achieved in patients fulfilling the clinical criteria, but also, 
to a much lesser extent, also in subjects with atypical phenotypic 
features, whereas also heterozygous mutation carriers can suffer 
from an incomplete and even typical disease (17). For all these 
reasons, the detection of a single heterozygous mutation, in the 
presence of clear clinical symptoms, appears to be a sufficient 
prerequisite for a colchicine trial (23).
HiDS/Mevalonate Kinase Deficiency 
(MKD)
Periodic fever associated with MKD was originally identified 
in 1984 in patients of Dutch ancestry; they reported recurrent 
attacks of fever of unknown origin and a high serum IgD level 
(26). After this first description, the disease was named Dutch 
fever or HIDS. After the first report, MKD was then described in 
other European countries around the Mediterranean basin (27) 
and Asia (28).
Because of the low sensitivity and specificity of the raised IgD 
serum levels, the term HIDS has been replaced by periodic fever 
associated with MKD after the discovery of the causing muta-
tions in the MVK gene (OMIM *251170) located on chromosome 
12q24 (29).
Mevalonate kinase deficiency, also known as hyperimmuno-
globulinemia D syndrome (OMIM 260920) is characterized by 
an autosomal recessive Mendelian inheritance pattern (5) and 
is allelic to another disorder, mevalonic aciduria (MA, OMIM 
610377), characterized by a very low activity of the enzyme MVK.
As in other AIDs, the carrier rate of 1/350 in normal popula-
tion allowed to hypothesize a selective advantage for heterozy-
gous carriers; a possible explanation postulates that countries 
with a diet at high consumption of saturated animal fats rich in 
cholesterol could have selected heterozygous carriers of the most 
frequent MVK mutations (30); nevertheless, this theory has not 
been demonstrated and other possible explanations are possible.
So far more than 130 substitutions or deletions of the MVK 
gene have been reported (16), even if a small number of muta-
tions (V377I, I268T, H20P, and P167L) represent the 71.5% of the 
whole mutation spectrum in MKD patients (29).
Several genotype–phenotype associations have been 
described. The most common mutation is the V377I variant, 
which is associated with a mild phenotype of MKD and some 
residual MVK activity. V377I is frequently found in a compound 
heterozygous state in most MKD patients (5, 31). At the opposite 
hand, some variants (i.e., V310M, A334T) are closely associated 
with a severe MA phenotype and severely impaired cellular MVK 
activity (32).
Interestingly, the H20P and I268T mutations have been 
described in intermediate phenotype, either with MA and 
MKD clinical signs, such as fever attacks associated with some 
neurological manifestations (mental retardation, cerebellar 
ataxia) of variable severity (33), leading to the hypothesis that 
the two diseases may represent the two extremities of the phe-
notypic spectrum which depends on the type (truncating vs 
non-truncating) of the mutations or the degree of impairment 
of the MVK enzyme activity. For example, mutations resulting 
into a MKD phenotype are exclusively missense, associated with 
a mild reduction of the enzymatic activity whereas in the MA 
phenotypes, frameshift and nonsense mutations are commonly 
reported (16), which completely inactivate the gene function. In 
fact, the MVK gene encodes the enzyme MVK, involved in the 
ATP-dependent phosphorylation of mevalonic acid into 5-phos-
phomevalonate. Mutations affecting this gene alter the MVK 
activity, with an overproduction of proinflammatory isoprenoids, 
reduced synthesis of cholesterol, and accumulation of mevalonic 
acid in plasma and urine. Fever rushes may be caused by high 
release of IL-1β as a consequence of insufficient geranylgeranyl 
pyrophosphate generation (32). The development of fever may 
be caused by a dysregulation of the MVK pathway, but the patho-
genetic mechanisms leading to the autoinflammation remain to 
be clarified.
Tumor Necrosis Factor Receptor-
Associated Periodic Syndrome
Tumor necrosis factor receptor-associated periodic syndrome 
(OMIM 142680) is the most common autosomal dominant AID 
in Europe; it was initially named “familial Hibernian fever” from 
the ancient Latin name “Hibernia” given to Ireland. In fact, in 
1982, a large family from Scotland and Ireland was described 
with a new disorder, characterized by recurrent fevers, skin 
rashes, monocytic fasciitis, and abdominal pain (2). Since the 
first description, several cases have been identified in many other 
populations, such as Black Americans, Japanese, and patients of 
Mediterranean ancestry (34).
In 1998, the genetic basis of this condition was discovered and 
the name became TRAPS due to its relationship with the p551A 
receptor of TNF (TNFR1), encoded by the TNF super family 
receptor 1A (TNFRSF1A) gene (1, 2), whose mutations cause 
the disease. The TNFRSF1A gene is composed of 10 exons with 
the disease causing mutations, all missense and heterozygous, all 
concentrated into exons 2, 3, 4, and 6 (2). Based on the mutation 
position, they can be distinguished as high- or low-penetrance 
missense mutations. The high-penetrance mutations are located 
in cysteine-rich N-terminal domains, which are important 
for the assembly of the receptor’s three-dimensional structure 
(35, 36); furthermore, they cause an early disease onset and more 
severe clinical manifestations; the substitutions result in single 
7Martorana et al. Genetics of Monogenic AIDs
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amino acid substitutions in the cysteine rich domains (CRDs) 
1, 2, or 3 of the ectodomain of the mature TNFR protein (37). 
These CRDs are involved in disulfide bond formation and in 
the folding of the extracellular portion of the protein. On the 
other hand, the TNFRSF1A low-penetrance mutations, such 
as R92Q and P46L, are associated with lower risk of amyloi-
dosis and adult-onset, milder and/or atypical clinical features 
(16, 38–40); for instance, the P46L substitution occurs in up to 
20% of clinically asymptomatic West African individuals, which 
suggests that it represents a polymorphism rather than a disease-
causing mutation, whereas the R92Q substitution, relatively 
common in the Caucasian population, is a low-penetrance vari-
ant, which could have a weak contribution to disease expression. 
Moreover, TNFRSF1A mutations affecting TNF receptor shed-
ding from cell membranes might potentially generate a selective 
advantage related to an increased antibacterial capacity (41). More 
in general, it can be assumed that, on the contrary to other fully 
penetrant autosomal dominant disorders, like neurofibromatosis 
type I (OMIM #162200), in which the new cases of the disease 
are all caused by new mutations in the NF1 gene, the new cases 
of TRAPS belong to families in which the mutation segregates 
through the generations without giving manifest signs of disease. 
For this reason, in each proband, a careful family history for the 
cardinal signs of recurrent fevers, fasciitis, and cutaneous rash 
should always be collected.
Based on the difficulties with a clinical diagnosis of AID, 
a genetic test is useful in case of patients with clinical TRAPS 
phenotype, and a genetic diagnosis of TRAPS can be performed 
in the presence of a mutation in TNFSRF1A. Routine diagnos-
tic analysis is limited to the exons 2, 3, 4, and 6, whereas the 
expansion of the analysis to the remaining coding regions of the 
gene is recommended only for cases with extremely suggestive 
phenotypes yet without a definitive diagnosis. In the absence of a 
family history and with borderline phenotypes, the probability of 
mutation finding with the extension of the genetic analysis to the 
whole gene remains very low and the decision should be carefully 
discussed with the clinician.
At pathogenic level, several mechanisms may be responsible 
for the disease onset, such as impaired TNF receptor shedding, 
defective intracellular TNF receptor trafficking to the cell surface, 
and subverted TNF-independent cell activation with increased 
production of IL-1 and IL-6, altered NF-κB pathway, increased 
activation of mitogen-activated protein kinases, and upregulated 
production of reactive oxygen species (42, 43).
The molecular link between TRAPS and IL-1 is not clear: the 
pathogenesis may vary with each mutation, but it is possible that 
IL-1 might act as a proinflammatory mediator downstream of 
TNF, or that aggregates of misfolded TNF receptors stimulate 
intracellular signals resulting in enhanced production of IL-1 and 
other chemokines (44).
Cryopyrinopathies (FCAS, MwS, and 
NOMiD)
Familial cold autoinflammatory syndrome (OMIM 120100), 
MWS (OMIM 191900), and CINCA syndrome (OMIM 607115), 
also known as neonatal onset multisystem inflammatory disease 
(NOMID), are autosomal dominant disorders (45–47) caused 
by mutations in the NLRP3 (NOD-like receptor 3, cold-induced 
autoinflammatory syndrome 1, also named CIAS1) gene, encod-
ing for the cryopyrin protein, an important inflammasome pro-
tein that directly activates IL-1β (48). Until 2001, these diseases 
were considered as three different diseases. Since 2001, mutations 
in the NACHT domain of the NLPR3/CIAS1 gene were linked to 
FCAS and MWS (49, 50), whereas mutations in the same gene 
were identified in 2002 in sporadic cases with NOMID/CINCA 
(48, 51); after these evidences, the three disorders were grouped 
under the family of CAPS. FCAS and MWS are usually familial 
(49), while NOMID/CINCA is sporadic (52, 53).
Cryopyrin-associated periodic syndromes are rare diseases, 
with an estimated prevalence of approximately 1–2 patients per 
1,000,000 people in Europe and in the USA (54).
Familial cold autoinflammatory syndrome, MWS, and 
NOMID/CINCA share a significant symptom overlap (55), with 
the latter described across the world as the most severe expression 
of CAPS (56).
In Infevers database, 175 different nucleotide variants and 
more than 90 heterozygous mutations on the NLRP3 gene have 
been described to date (16, 57). Mutations in NLRP3 gene are 
described in approximately 60% of CAPS patients, causing the 
constitutive activation of the inflammasome and dysregulation 
with IL-1 overproduction; excessive IL-1 signaling appears to be 
a constant feature in the background of CAPS, driven by gain-of-
function NLRP3 mutations, even in the absence of a second signal 
(58). As in all the AIDs, genetic testing is confirmatory, even if the 
diagnosis needs to be made on clinical symptoms.
More than 40% of NOMID/CINCA patients and a less percent-
age of FCAS and MWS patients do not carry germ-line mutations 
in NLRP3. In those patients, somatic mosaicism occurring during 
fetal development may explain the variation in disease onset (59); 
this mechanism can only be demonstrated by cell cloning and 
next-generation sequencing (NGS).
Genotype–phenotype correlations were demonstrated in 
CAPS, with some mutations associated only with a mild clinical 
phenotype, and others with severe clinical pictures. However, 
several cases were reported in which patients with the same 
mutations present different phenotypes (60, 61). Furthermore, 
some NLRP3 mutations are described in healthy subjects with 
no signs of CAPS, such as V198M and Q703K genetic variants, 
even if there is no apparent selective advantage demonstrated for 
CAPS (62). Nevertheless, when patients who carry these poly-
morphisms show CAPS symptoms, the IL-1β-inhibition response 
is diminished. As in the other AIDs, functional polymorphisms 
may be considered low penetrance mutations, able to influence 
the activity of the gene product (58, 63).
In conclusion, CAPS onset may be influenced by environ-
mental factors and genetic determinants, which are also able to 
modulate the disease phenotype.
Deficiency of interleukin-1 Receptor 
Antagonist
Deficiency of IL-1 receptor antagonist is a recently described 
autosomal recessive disease due to mutations of IL1RN that 
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lead to non-expression of the encoded protein, IL-1 RA, causing 
unopposed IL-1 receptor activation and increased response to 
IL-1α and IL-1β stimulation (64).
The disease was first described in 2009 in nine patients 
presented with sterile multifocal osteomyelitis, periostitis, and 
pustulosis since the neonatal period, without fever. IL1RN gene 
was sequenced in those DIRA patients (6): either homozygous 
for mutations in IL1RN or heterozygous parents were identi-
fied. A patient was homozygous for two nucleotides deletion 
(c.156_157delCA) that caused a frame-shift mutation named 
N52KfsX25, followed by the incorporation of 24 aberrant amino 
acids and a termination codon. Both parents were heterozygous 
carriers of the same mutation. In other patients, three were 
homozygous for a nonsense variant affecting the amino acid 
residue at position 77 (c.229G>T; p.E77X). Patients from a con-
sanguineous Lebanese family were homozygous for a nonsense 
mutation (c.160C>T, p.Q54X). Patient 9, from Puerto Rico, was 
homozygous for a deletion of approximately 175 kb on chromo-
some 2q that includes six genes from a cluster of IL-1-related genes: 
IL1RN and the genes encoding IL-1 family, members 9 (IL1F9), 
6 (IL1F6), 8 (IL1F8), 5 (IL1F5), and 10 (IL1F10). The IL1RN 
mutations are present in founder populations in Newfoundland, 
the Netherlands, Puerto Rico, and possibly Lebanon and further 
founder mutations have since been found in other populations 
(65). None of these mutations were found in DNA specimens 
obtained from a panel of 364 controls from the New York Cancer 
Project.
In 2011, two unrelated Brazilian patients whose clinical phe-
notype was consistent with the DIRA syndrome were described 
(66). Both were homozygous for the same 15-bp (in-frame) 
deletion on IL1RN. This novel mutation of IL1RN produces 
a protein that does not bind the IL-1 receptor, and thus lacks 
functional activity. The authors hypothesize that this variant 
is likely to be a possible founder mutation in the Brazilian 
population.
In 2012, a novel nonsense mutation (p.Q119X) in IL1RN 
gene was identified in two Turkish patients with consanguineous 
parents (67).
Blau Syndrome (BS)
Blau syndrome is an autosomal dominant granulomatous inflam-
matory disease caused by mutations in the NOD2/CARD15 
gene. This gene is located on chromosome 16q12 and encodes 
the three domain cytosolic protein of almost 1000 amino acids, 
the nucleotide-binding oligomerization domain containing 2 
(NOD2). The protein contains two N-terminal CARDs for down-
stream signaling through CARD–CARD interactions, a central 
nucleotide binding and oligomerization domain (NACHT) 
with ATPase activity, and nine C-terminal LRRs for pathogen-
associated molecular patterns (68).
Mutations in the NOD2/CARD15 gene cause alteration in 
single amino acids in the NOD2 protein, resulting in an overac-
tive version, which may lead to abnormal inflammatory reaction.
More details on the pathogenic aspects of BS were obtained 
from the identification in four European families of three mis-
sense mutations in 2001. Two of these families shared the same 
mutation, encoding an amino acid substitution of arginine to 
tryptophan in position 334 (R334Q), one family had an R334W 
and another L469F substitution (69).
The following year, another study on the genetic analysis of 
NOD2 coding regions based on 10 families with BS was published 
(70). In five of the families, two sequence variants at position 
334 of the gene product (R334W and R334Q) were identified. 
Affected family members from the original BS kindred, included 
in this study, were heterozygous for the R334W missense muta-
tion; mutations at the same position were also observed in several 
unrelated BS families, some of whose phenotypes included large-
vessel arteritis and cranial neuropathy. The missense mutations 
were segregated with the disease phenotype in the families and 
were not identified in 104 healthy controls.
To date, on a total amount of almost 220 patients with BS 
carrying CARD15/NOD2 mutations, missense substitutions of 
R334Q/R334W account for more than 80%, causing a genetic hot 
spot for mutations in codon 334. E383K has been found in almost 
5% of patients, whereas other mutations have been described 
most rarely (71).
The number of NOD2 variants associated with BS has 
expanded greatly. In fact, up to 2016, the number of sequence 
variants of NOD2 gene is 144 (140 substitutions, 3 deletions, and 
1 insertion) (16). There are no known mutations involving the 
untranslated and the intronic regions of the gene, even though 
this has not been extensively studied.
Despite the striking clinical similarities between them, for 
many years BS was considered a distinct entity from early onset 
sarcoidosis (EOS). Genetic analyses showed that many patients 
with EOS carry mutations in CARD15/NOD2 gene; hereafter, 
some authors proposed that BS and EOS are the familial and spo-
radic forms of the same disease (71). Moreover, CARD15/NOD2 
gene mutations described in BS and EOS are mainly located in the 
NACHT domain of the protein. The discovery of CARD15 muta-
tions in BS families encouraged to investigate similar CARD15 
mutations in EOS patients.
Among 10 EOS cases retrospectively collected in Japan, 
heterozygous missense mutations were found in nine cases; 
four showed a c.1000C>T (p.R334W in amino acid change) 
that has been reported in BS, four showed novel c.1487A>T 
(p.H496L), c.1538T>C (p.M513T), c.1813A>C (p.T605P), and 
c.2010C>A (p.N670K), and one case showed double c.1146C>G 
(p.D382E)/c.1834G>A (p.A612T) mutations on different alleles. 
The study concluded that EOS is closely related with CARD15 
mutations causing constitutive NF-B activation and shares the 
common genetic etiology with BS (72).
Deficiency of the iL-36 Receptor 
Antagonist (DiTRA)
Deficiency of the IL-36 receptor antagonist is a recently described 
autosomal recessive autoinflammatory syndrome caused by 
mutations in the IL36RN gene, characterized clinically by recur-
rent episodes of generalized skin pustulation, fever, systemic 
inflammation, and leukocytosis. Other phenotypes of the IL36RN 
mutation include related pustular disorders, palmoplantar 
pustulosis, acrodermatitis continua of Hallopeau (ACH), and 
acute generalized exanthematous pustulosis. Histology shows 
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spongiform pustules, acanthosis, and parakeratosis and an abun-
dance of CD3+ and CD8+ T cells and macrophages (73).
This gene encodes IL-36 receptor antagonist (IL-36Ra), a 
protein belonging to the IL-1 cytokine family responsible for the 
tight regulation of IL-36 signaling. The IL-36 pathway is activated 
after binding of one of the three IL-36 agonists (IL-36b α, β, 
and γ) to a common specific receptor IL-1Rrp2, leading to the 
recruitment of the co-receptor IL-1 receptor accessory protein 
(IL-1RacP) and subsequent activation of intracellular NF-κB and 
mitogen activated protein kinase pathways (74).
Several mutations were highlighted in IL36RN gene with 
different effects. All IL36RN null mutations, such as c.28C>T 
(p.Arg10X), c.41C>A (p.Ser14X), c.80T>C (p.Leu27Pro), 
c.227C>T (p.Pro76Leu), c.280G>T (p.Glu94X), c.368C>G 
(p.Thr123Arg), c.368C>T (p.Thr123Met), and c.420_426del 
(p.Gly141MetfsX29) were totally unable to antagonize the IL-36 
mediated activation of the NF-κB signaling pathway (75–83).
Among the most frequent genetic alterations is one 
Tunisian founder missense mutation: c.80C>T (p.Leu27Pro1); 
one European recurrent missense mutation: c.338C>T 
(p.Ser113Leu2); and one Japanese founder nonsense mutation: 
c.28C>T (p. Arg10*3).
The mutations c.95A>G (p.His32Arg), c.142C>T (p.Arg48-
Trp), and c.308C>T (p.Ser113Leu) only partly reduced the 
expression level of the corresponding IL-36Ra and consequently 
the capacity to repress the IL-36 mediated NF-κB signaling 
cascade. The detection of c.104A>G (p.Lys35Arg) and c.304C>T 
(p.Arg102Trp) mutations do not produce evident alterations in 
either protein expression and function, raising doubt about the 
actual pathogenic contribution of these genetic variants. They 
are classified as damaging by the pathogenicity prediction tools, 
such as SIFT and/or PolyPhen. For these mutations, additional 
functional studies are warranted to understand whether these 
variants truly have an effect on disease development or if they 
are polymorphisms (74).
Recently, Cordoro et  al. showed a homozygous mutation 
within the IL36RN gene at position c.115+6T>C in a male ado-
lescent with generalized pustular psoriasis (GPP) since infancy. 
This mutation has been shown to lead to a splicing defect result-
ing in exon skipping and a premature stop codon, leading to a 
truncated IL36Ra protein (81).
In summary, the c.28C>T (p.Arg10X) and c.115+6T>C 
(p.Arg10ArgfsX1) transitions are known to be founder muta-
tions in cases reported in Japan (84). The c.115+6T>C transition 
is also recurrently found in Chinese and Malaysian patients 
(81, 85). The c.80C>T (p.Leu27Pro) transition is a recurrent 
mutation in Africa, and the c.338C>T (p.Ser113Leu) transi-
tion is a recurrent mutation in Europe (79–81). In contrast, the 
c.368C>T and c.368C>G transitions have been reported in one 
case in Japan (75, 76), the c.104A>G (p.Lys35Arg), c.142C>T 
(p.Arg48Trp), and c.304C>T (p.Arg102Trp) have been reported 
in one and two cases in Europe, respectively.
More in general, the null mutations are consistently associated 
with the more severe phenotypes of GPP and acute exanthema-
tous generalized pustulosis (86, 87), whereas the hypomorphic 
alleles usually show a milder phenotypic expression featured by 
localized variants of palmoplantar pustular psoriasis (PPP) and 
ACH, although generalized pustular phenotypes can be observed 
as well in carriers of mild variants. The detection of the same gene 
variants in generalized and localized pustular phenotypes sug-
gests the pathophysiological contribution of other factors such as 
disease-modifying genes, environmental factors, and epigenetic 
events, which may all influence disease onset, expression, and 
severity.
Chronic Atypical Neutrophilic Dermatosis 
with Lipodystrophy and elevated 
Temperature (CANDLe) Syndrome
Chronic atypical neutrophilic dermatosis with lipodystrophy and 
elevated temperature syndrome is a rare autosomal recessive AID, 
with less than 100 cases described worldwide (88).
The CANDLE syndrome is caused, in the majority of cases, 
by homozygous mutations in PSMB8 gene, which encodes for a 
proteasome protein (89). There are evidences that an increase of 
modified and oxidated proteins occurring in fat and tissue cells, 
due to mutations of PSMB8 lead to an augmentation of cellular 
stress and apoptosis (88).
In 2012, a genome-wide analysis of nine CANDLE syndrome 
affected patients in eight families suggested that mutations in 
PSMB8 gene may cause the CANDLE syndrome. In this cohort, 
four patients were homozygous and two were heterozygous for 
a missense mutation (p.T75M), two patients were homozygous 
for a nonsense mutation (p.C135X), and one patient showed no 
mutations. None of these gene variants were observed in 750 
healthy controls. Furthermore, only two of the four patients 
with the same mutation shared the same haplotype, indicating a 
possible mutational hot spot (90). Later, in 2015, a diagnosis of 
CANDLE syndrome was performed by targeted sequencing of 
one 3-year-old CANDLE syndrome Hispanic male patient, born 
to consanguineous healthy parents. A homozygous c.280G>C, 
p.A94P mutation in PSMB8 gene was not observed in any public 
genetic databases and was predicted to be pathogenic by several 
prediction tools (91).
Recently, it was demonstrated that CANDLE syndrome can 
also be caused by mutations in genes that encode other protea-
some subunits, such as PSMB4, PSMB9, and PSMA3 (92); these 
mutations affect transcription, protein expression, protein fold-
ing, proteasome assembly, and, eventually, proteasome activity.
Majeed Syndrome
Majeed syndrome is a congenital predisposition to develop early-
onset multifocal osteomyelitis (CRMO), congenital dyserythro-
poietic anemia (CDA), congenital anemia, and inflammatory 
dermatosis, resulting from the infiltration of neutrophils into 
the dermis (93). It is transmitted with an autosomal recessive 
pattern of inheritance and is caused by mutations in the LPIN2 
gene, which maps on chromosome 18p. The genomic sequence of 
LPIN2 is approximately 95 kb and comprises 20 exons, of which 
exon 1 and the majority of exon 20 are non-coding (5ʹ and 3ʹ 
untranslated regions). The mRNA is approximately 6245 bp and 
encodes a protein of 896 amino acids, which is expressed in almost 
all tissues (94). LIPIN2 derives its name from its highly conserved 
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N-terminal and C-terminal LIP domains. LIPIN-1, -2, and -3 
are phosphatidate phosphatases (PAPs), which are important 
in glycerolipid biosynthesis and as transcription co-activators 
regulating lipid metabolism genes (95). In addition, lipin-2 regu-
lates increased IL-1β formation in primary human and mouse 
macrophages by several mechanisms, including activation of the 
inflammasome NLRP3. In macrophages, reduced levels of lipin-2 
cause a decrease of cell cholesterol levels. In conclusion, lipin-2 is 
able to down-regulate NLRP3 inflammasome (91).
Several mutations have been identified in LPIN2 gene. One 
of them, the c.540-541delAT (p.Cys181Ter), is a frameshift 
mutation that produces a premature stop codon producing 
a truncated protein that is 180 amino acids long; a second 
variant, the c. 2201C>T (p. Ser734Leu), is a missense mutation 
that replaces a highly conserved serine with a leucine (96). 
Al-Mosawi et  al. report a third unique mutation in LPIN2 in 
an Arabic female with CRMO and CDA. The c. 2327+1G>C 
(p.Arg776SerfsTer66) nucleotide change affects a highly con-
served nucleotide residue at the 5ʹ (donor) splice site of exon 17 
and it is predicted to introduce a frameshift mutation resulting in 
a premature stop codon being encountered in intron 17, which 
would be predicted to produce a truncated message (97). A novel 
homozygous 2  bp deletion (c.1312_1313delCT) resulting in a 
premature stop codon (p.Leu438fs+16Ter) and consequently 
in a truncated LIPIN2 protein was recently described in two 
Turkish brothers with MS who were treated successfully with 
IL-1 inhibitors (7).
LPIN2 shares homology with LPIN1, which has been shown 
to play a role in murine lipodystrophy (98). The role of LPIN2 
mutations in producing the inflammatory phenotype of MS is 
not clear and does not appear to involve a disturbance in lipid 
metabolism. LPIN2 has an amino-terminal lipin domain, a Lipin/
Ned1/Smp2 domain, and a putative nuclear localization signal. 
Lipin2 also has PAP type-1 activity and may play a role in lipid 
biology (99).
Although the number of individuals reported with MS is too 
small to study genotype–phenotype correlations, the affected 
individuals with a frameshift variant appear to have a more severe 
course and complications than individuals with other classes of 
pathogenic variants (100). More recent observations, however, 
have indicated that an affected individual with a splice site 
variant (97) and two affected Turkish brothers with a frameshift 
variant (7), who were all diagnosed and treated early, had a less 
complicated course. It is unclear whether their milder clinical 
course is attributable to the earlier detection and treatment.
CARD14-Mediated Pustular Psoriasis 
(CAMPS)
CARD14 encodes caspase recruitment domain family member 14 
(CARD14). It is known to be specifically expressed in the skin and 
to be localized mainly to keratinocytes. CARD14 is a scaffolding 
protein that regulates NF-κB activation. The NF-κB family of 
transcription factors plays a crucial role in cell activation, sur-
vival, and proliferation and results in cancer, immunodeficiency, 
or autoimmune disorders (e.g., psoriasis). Hence, the presence 
of the CARD14 mutations may result in greater amplitude of 
inflammatory response upon epidermal activation. The skin 
disease in patients with CARD14 mutations can be limited or 
generalized. Autosomal dominant or sporadic gain-of-function 
mutations in the CARD14 gene cause GPP (101), familial 
pityriasis rubra pilaris (PRP) (102), psoriatic arthritis (PA) (103), 
PPP (104), and even pustular psoriasis suggesting a large disease 
severity spectrum. Fever and other systemic manifestations are 
generally not present but can occur with superinfections of the 
skin.
Three variants, c.349G>A (p.Gly117Ser), c.205C>T (p.Arg69 
Trp), and c.589G>A (p.Glu197Lys), affect the N-terminal  region 
of the protein harboring its caspase recruitment domain or 
coiled-coil domain but with different effects. The c.589G>A 
(p.Glu197Lys) and c.349G>A (p.Gly117Ser) lead to upregulation 
of NF-κB activity, whereas the c.205C>T (p.Arg69Trp) leads 
to a sevenfold downregulation. In particular, the c.349G>A 
(p.Gly117Ser) variant described in a family of European descent 
altered the splicing between CARD14 exons 3 and 4. One Tunisian 
patient was reported with a c.1356+5G>A splice alteration which 
is predicted to lead to the skipping of exon 9, which encodes part 
of the coiled-coil domain (105). Mutations in CARD14, includ-
ing p.Glu138del and p.Leu156Pro, have been associated with 
autosomal-dominant pityriasis rubra pilaris, which is phenotypi-
cally related to psoriasis (102).
Several gain-of-function variants/mutations in CARD14 have 
been reported to be a predisposing factor for psoriasis vulgaris 
(PV) in a large family with PV and PA. Jordan et al. identified the 
rare de novo CARD14 gain-of-function variant p.Glu138Ala in a 
child with severe early-onset GPP. They also found rare CARD14 
gain-of-function variants in large PV cohorts by the NF-κB assay, 
which revealed that compared to the wild-type CARD14, the 
p.Gly117Ser, p.Glu138Ala, and p.Asp176His variants were associ-
ated with increased levels of the luciferase reporter. Additional 
rare variants within CARD14 are c.424G>A (p.Glu142Lys), 
c.511C>A (p.His171Asn), c.536G>A (p.Arg179His), and 
c.571G>T (p.Val191Leu) (106).
In conclusion, the above-reported data concur to reach the 
following conclusions: (1) differences in the genetic background 
among different geographic populations account for significant 
variances observed in psoriasis populations, both in terms 
of frequency and of severity (localized palmoplantar versus 
generalized forms) of pustular psoriasis (107, 108), (2) despite 
the dramatic in  vitro effects of some CARD14 variants on the 
keratinocytes, there is a wide range of phenotypes, even among 
individuals who carry the same substitution, suggesting that in 
many instances, the variable phenotypes are likely to multiple 
other factors besides the genetic background.
NLRP12-AiD
NLRP12 is an NLR encoded by NLRP12 (also known as NALP12, 
Monarch-1, or PYPAF7) and functions as a negative regulator of 
NF-κB activation (109). NLRP12 interacts via its pyrin domain 
with the pyrin domain of apoptosis-associated speck-like (ASC) 
protein (110) leading to the formation of an intracellular aggregate 
called speck to active IL-1B (111). Sequencing of NLRP12 revealed 
a heterozygous nonsense mutation c.850C>T (p.Arg284X) in 
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identical twin brothers presenting with symptoms overlapping 
FCAS and MWS. A second NLRP12 mutation (c.2072+3insT) 
was identified in a patient presenting with a periodic fever syn-
drome, including clinical manifestation of FCAS. This mutation, 
affecting the donor splice site of intron 3, activates a cryptic 
splice site located upstream in exon 3 and results in a frameshift, 
followed by a premature stop codon (112). These two mutations 
were demonstrated to be functionally associated with high levels 
of NF-κB activity, thus accounting for the autoinflammatory 
phenotype. Jèru et al. identified a missense mutation c.1054C_T 
(p.Arg352Cys) within the NBS domain of the protein in two 
unrelated patients. This missense mutation is associated with a 
gain of function of caspase 1 processing (110). The c.882C>G 
(p.Asp294Glu) mutation was found to mostly segregate with a 
particular sensitivity to cold exposure (especially arthralgias 
and myalgia), even in the absence of urticarial rash, fever, or 
elevation in the levels of acute-phase reactants. In any case, the 
clinical manifestations presented by the carriers were generally 
mild, although quality of life was affected, especially during the 
winter season (112–114). Several reports identified the NLRP12 
variant F402L (c.1206 C>G) (115–117).
Pyogenic Arthritis, Pyoderma 
Gangrenosum, and Acne (PAPA) Syndrome
Pyogenic sterile arthritis, pyoderma gangrenosum, and acne 
syndrome is an autosomal dominant AID caused by mutations 
in the PSTPIP1 gene, which is located in chromosomal position 
15q24–q25.1. Pyrin protein is a cytosolic receptor for PSTPIP1. 
Ligation between pyrin and PSTPIP1 induces pyrin to interact 
with ASC protein, inducing the creation of an active ASC 
pyroptosome. A possible explanation of PAPA syndrome is a 
constitutive ligation and consequent activation of pyrin with the 
mutated PSTPIP1 proteins (112). The disease is extremely rare, 
with less than 10 families described worldwide. The first case 
of PAPA syndrome was reported in 1975 (118) and in 1997, in 
the same family, PAPA syndrome was described as a heritable 
disease (119).
In 2000, 93 genomic loci were investigated in patients with a 
pleiotropic inflammatory syndrome characterized by pyoderma 
gangrenosum, cystic acne, and erosive arthritis, demonstrating 
PAPA syndrome maps in chromosomal position 15q (120).
There are two hot-spots mutations, c.688G>A (p.A230T) 
and c.748G>C (p.E250Q), which occur in exons 10 and 11 and 
have been found in many familial (121–126) and sporadic cases 
(127, 128). Mutations are thought to disrupt the binding of 
PSTPIP-1 with protein tyrosine phosphatase–PEST, a regula-
tory phosphatase, increasing its avidity for pyrin in the cytosol, 
thereby causing dysregulation of IL-1β production (129).
Until 2016, a total of 27 genetic variants were reported for 
PSTPIP1 gene (23 substitutions, 1 insertion, 2 deletions, and 1 
duplication), 17 of which are PAPA phenotype associated (16).
Deficiency of Adenosine Deaminase 2
Searching for mutations in systemic inflammation and vasculop-
athy and/or necrotizing vasculitis polyarteritis nodosa patients, 
CECR1 (cat eye syndrome chromosome region, candidate 1) gene 
mutations were discovered by two independent groups. Pattern 
of inheritance was autosomal recessive. Subsequent studies 
described another case with a fatal vasculopathy (130). Common 
clinical signs are early onset recurrent stroke, neurologic manifes-
tations, and fever. Being the CECR1 gene highly polymorphic, as 
other AID causative genes, the correlation between clinical signs 
and familial ancestry is important. The CECR1 gene encodes 
the adenosine deaminase 2 (ADA2) protein, which has partial 
homology with ADA1 protein. Both ADA1 and ADA2 act as 
intracellular enzymes that regulate the purinergic signaling path-
way. Mutations in ADA1 are known to cause severe combined 
immunodeficiency disease, characterized by a defect in T- and 
B-lymphocytes. ADA2 mutations, conversely, cause only mild 
hypogammaglobulinemia due to a defect in terminal differentia-
tion of B-cells (131).
NLRC4-Associated inflammatory Diseases 
(SCAN4, NLRC4-MAS, and NLRC4-FCAS)
Patients with macrophage activation syndrome or a milder 
phenotype like FCAS may carry gain of function mutations in 
the NLRC4 (IPAF; CARD12) gene (132–134). Two novel causal 
mutations, p.T337S and p.V341A, have been diagnosed by whole 
exome sequencing (WES) in two sporadic patients (trios); the 
reported clinical symptoms were early onset fever, failure to 
thrive, rash, joint pain, and elevated inflammatory markers, 
including hyperferritinemia (133). The two mutations map in a 
highly conserved HD1 region of the NLRC4 nucleotide-binding 
domain and may decrease the function of NLRC4 to maintain 
itself in an auto-inhibited state. A third mutation, p.H443P, was 
identified in a Japanese family with milder symptoms including 
cold induced rash, fever, and arthralgia, even if the patient has 
a different phenotype from those other two previously patients 
reported. Mutations are supposed to regulate the mutant 
proteins into a constitutively active state, with the influence of 
environmental factors such as cold and stress which act as trigger, 
causing inflammasome activation. Further studies are necessary 
to explore full spectrum of monogenic inflammasome-related 
diseases. Interestingly, the NLRC4 gene (IPAF, CARD12) is sup-
posed to initiate inflammation in response to bacterial ligands, 
such as flagellin (135, 136).
Stimulator of interferon Genes (STiNG)-
Associated vasculopathy with Onset in 
infancy
In a trio with a patient affected by early onset symptoms of systemic 
inflammation, cutaneous rash, and pulmonary manifestations, 
and his unaffected parents, WES was performed, identifying a de 
novo mutation, p.N154S, in the TMEM173 gene; this gene encodes 
for a STING (138). Extending the analysis to other five sporadic 
cases of different ancestries but with similar phenotype led to 
the identification of missense mutations in the TMEM173 gene. 
Functional studies showed that a particular missense mutation, 
p.V155M, has been previously associated with a phenotypically 
different disease like systemic lupus erythematosus (139). Most of 
the mutations are located in the exon 5 of TMEM173 gene, which 
encodes for a domain important for the STING dimerization site. 
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The second study highlights that in families with dominantly 
inherited traits, the possibility of reduced penetrance should not 
be ignored. Sting knockout mice are prone to viral infections, 
because of the lacking of the ability to upregulate IFN-beta (137). 
As a result, all these data support the evidence that TMEM173-
associated mutations are gain of function (138, 139).
TNFRSF11A-Associated Hereditary Fever 
Disease
Patients with this disease have a phenotype similar to those 
affected by TRAPS. In a single patient with complex phenotype 
including neonatal onset of systemic inflammation and congeni-
tal abnormalities, a de novo genomic duplication containing the 
TNFRSF11A gene was identified (140). The TNFRSF11A gene is 
one of the 30 genes in the 10-Mb genomic duplication. Another 
study, using a different approach based on candidate gene screen-
ing, identified two other patients (mother and daughter) with a 
novel heterozygous 1-bp deletion (p.Met416Cysfs*110) in exon 9 
of TNFRSF11A gene. The resulting protein lacks the C-terminal 
intracellular domain. As TNFRSF1A, also TNFRSF11A gene 
encodes for a protein member of the TNF-receptor superfamily. 
TNFRSF11A (RANK, PDB, ODFR) gene encodes a signaling 
receptor that functions in osteoclast differentiation and bone 
remodeling (141, 142). RANK-ligand (RANKL) mediates essen-
tial signal for osteclastogenesis (143).
Rank-deficient mice present osteopetrosis caused from a block 
in osteoclast differentiation and the lack of peripheral lymph 
nodes (144). The pathogenesis of this disorder is unclear; in fact, 
the TNFRSF11A gene duplication suggests a gain of function 
mutation, while the heterozygous deletion is more consistent 
with a haploinsufficiency or a dominant negative effect.
TRNT1 Deficiency
Patients presenting with a variable phenotype of congenital side-
roblastic anemia, B cell immunodeficiency, and developmental 
delay have been termed SIFD (145). SIFD is characterized by an 
early onset, with frequently associated neurological symptoms, 
and metabolic abnormalities. SIFD has been associated to AID 
because it is characterized with a pediatric onset with periodic 
fevers and gastrointestinal involvement with sideroblastic ane-
mia. Genetic cause of SIFD has been found in the TRNT1 gene 
in an autosomal recessive inheritance (146, 147). The TRNT1 
gene encodes the ubiquitously expressed CCA-adding enzyme, 
essential for template-independent maturation of nuclear 
and mitochondrial transfer RNAs (148). Functional studies 
in yeast showed deficiency of TRNT1 homolog causes partial 
loss of function of TRNT1 affecting variable degrees of enzyme 
activity (146). Knock-out yeast for TRNT1 was fully restored 
with human TRNT1 and partially rescued by human mutant 
proteins.
Monogenic Form of Systemic Juvenile 
idiopathic Arthritis
Systemic-onset juvenile idiopathic arthritis is a polygenic inflam-
matory disease characterized by fever, rash, and symmetrical 
polyarthritis, with persistent systemic inflammation that seems 
to be linked to altered innate immune system (149, 150). 
Mendelian inheritance is autosomal recessive. Studying five 
consanguineous families with 13 affected patients from the 
Saudi Arabia with several genomic approaches, such as linkage 
analysis, homozygosity mapping, and WES, a homozygous mis-
sense mutation, p.C284R, located in exon 4 of the laccase domain 
containing 1 (LACC1) gene was identified (151). This private 
mutation is highly conserved during evolutionary scale and was 
not described in more than 2,000 Arab controls, suggesting its 
role in the pathogenesis.
Laccase domain containing 1 gene belongs to a family of 
Laccases, multi-copper oxidoreductases able to catalyze the 
oxidation of a variety of phenolic and non-phenolic compounds. 
Protein function is largely unknown, even if may regulate the 
innate immune responses. In a recent study, the gene product of 
LACC1 gene has been named FAMIN (fatty acid metabolism–
immunity nexus), important for the synthesis of endogenous 
fatty acids and their mitochondrial oxidation, controlling the 
glycolytic activity and ATP regeneration (145).
Genetic variants in the LACC1 gene have been previously 
associated with susceptibility to leprosy (152–154). LACC1 gene 
belongs to a family of Laccases, multi-copper oxidoreductases 
able to catalyze the oxidation of a variety of phenolic and non-
phenolic compounds. Protein function is largely unknown, even 
if may regulate the innate immune responses.
GeNeTiC DiAGNOSiS wiTH New 
TeCHNOLOGieS
In recent years, with the increased use of instruments for NGS, 
it has become feasible to analyze several genes in a single experi-
ment. This method is of great interest for AID, because of the 
increasing number of genes associated with the different forms 
of AID. In some cases, it is difficult to differentiate the different 
diseases, in particular, in those patients with intermediate phe-
notypes or a difficult clinical diagnosis. The analysis of a panel 
of several candidate genes is feasible with targeted sequencing 
investigating causative mutations, rare variants, or regions associ-
ated with the disease.
With the large number of genetic variants found with NGS, it 
is extremely important to find information about their possible 
role in the development of a specific disease. Several softwares 
have been developed in recent years and most of them have been 
based on the assumption that protein sequences derived from 
living organisms have survived a natural selection. The goal is 
to find if a genetic variant is a causative mutation or a common 
polymorphism.
There is also the possibility to analyze all the 18,000 genes of 
the human genome. WES is a recent strategy designed to sequence 
only the coding regions of the genome (which represents 1% of 
the human genome, about 30 megabases); this is an effective 
method alternative to whole genome sequencing, cheaper and 
less complicated in the bioinformatical/statistical analysis. Exons 
are generally short, functional sequences of DNA which represent 
the portion of the genome translated in protein. The WES has 
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the potential to identify the coding variants responsible for both 
Mendelian and common diseases.
In recent years, with the use of WES, several undiagnosed 
Mendelian genetic conditions have been investigated in order to 
search the involved gene (155, 156). WES has been applied to 
the study of trios (unaffected parents and the sporadic case) and 
unrelated patients with phenotypic similarities. Identification of 
causal gene in a single sporadic patient can then be confirmed 
in other patients with similar phenotypes. The potential of such 
strategies is high in polygenic human disorders such as AID. The 
emerging genetic technologies complemented by the develop-
ment of public databases of human variation can allow discovery 
of disease causal genes in sporadic and unrelated patients.
Whole genome sequencing allows to sequencing the entire 
genomic DNA, both chromosomal and mitochondrial. Unlike 
WES, this method allows the sequencing of both exons and 
introns, for a total amount of 3 Gigabases.
In a single center study (157), more than 2,000 diagnostic 
patients have been analyzed with Sanger sequencing for the 
NLRP3, MVK and TNFRSF1A genes, and other AID gene 
portions, failing to find mutations in 86% of samples. Possible 
explanations of this high failure are the restricted number of 
tested genes, clinical misdiagnosis, genetic heterogeneity, and/or 
a complex mode of inheritance. In order to improve the sensitivity 
of the genetic tests, 50 patients were re-analyzed with a gene panel 
of 10 genes for NGS procedure. The 10 genes were MEFV, MVK, 
TNFRSF1A, NLRP3, NLRP12, NOD2, PSTPIP1, IL1RN, LPIN2, 
and PSMB8 (157). In order to better understand the possible role 
of the detected variants, allele frequencies have been compared 
with those of 1,000 Genomes Project, and searching for a possible 
genotype–phenotype correlation. Some genes, such as NOD2, 
LPIN2, and NLRP12, showed a high frequency of genetic variants, 
which in theory may alter the clinical phenotype with mild or 
atypical symptoms. In the next future, NGS data combined with 
clinical information may help diagnosis for those patients with 
intermediate phenotype (156); in fact, the interaction between 
geneticists and physicians will allow to improve the diagnosis of 
AID patients (157).
CONCLUSiON
In AID, genetic and environmental factors act modulating the 
clinical presentation of a specific disorder. The knowledge of 
the biological pathways at the basis of different AIDs is very 
important; the elucidation of these novel factors may have clinical 
relevance, because it may be included in genetic-risk modeling 
approaches. The genetic variants previously identified as playing 
a role in the same pathway represent new potential therapeutic 
targets. The new age of the -omics has allowed the improvement 
of the knowledge of AID. By means of genetic fine mapping, 
targeted sequencing, transcriptomics, proteomics, and metabo-
lomics, physicians may improve treatment and therapy tailored 
on the single patient.
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